In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can an Overthrown King Help Mylan?

Executive Summary

Mylan, one of the nation's top three generics companies, is offering to buy King Pharmaceuticals for $3.7 billion in a stock swap in order to boost its efforts in the branded pharmaceutical business. But the controversial proposal and reaction to it raises interesting questions about business models in specialty pharma, a concept that has, many ways, taken over the small-company pharma world.

Related Content

Teva/Ivax: Generics' Answer to Big Pharma
Teva/Ivax: Generics' Answer to Big Pharma
Kos/Biovail: How a Mid-Cap Can Win in Primary Care
Pliva: Two Steps Forward, One Step Back?
Authorized Generics: Band-Aid or Strategy?
Endo: Accessing Primary Care through Specialist Marketing
PSA 2004: Looking to the Sustainable Middle
Watson's Strategy for Beating the Big Boys
Elan Recovery Slowed By King
Mylan's New Focus


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts